Eliem Therapeutics, Inc

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 28658R106 since 12/18/2024, largest first.

Filer	% of Class	Shares	Form	Filed
RA Capital Management, L.P. 13D/A	33.0%	23,249,186	13D/A	7/7/2026 Event 7/2/2026
RA Capital Management, L.P.	33.0%	23,249,186
Peter Kolchinsky	33.0%	23,249,186
Rajeev Shah	33.0%	23,249,186
RA Capital Healthcare Fund, L.P.	24.1%	16,934,205
RA Capital Nexus Fund III, L.P.	6.4%	3,671,766
FMR LLC 13G	11.9%	6,790,364	13G	7/8/2026 Event 6/30/2026
FMR LLC	11.9%	6,790,364
Abigail P. Johnson	11.9%	6,790,364
Pontifax Management 4 G.P. (2015) Ltd. 13G	7.7%	5,206,380	13G	9/18/2025 Event 6/27/2024
Pontifax VI G.P. L.P.	7.7%	5,206,380
Pontifax Management 4 G.P. (2015) Ltd.	7.7%	5,206,380
Ran Nussbaum	7.7%	5,206,380
Tomer Kariv	7.7%	5,206,380
Under 5%, checked the "5 percent or less" box, or amended by a later filing (3)
AI Eti LLC 13D/A	0%	0	13D/A	10/16/2025 Event 10/14/2025
AI Eti LLC	0%	0
Access Industries Holdings LLC	0%	0
Access Industries Management, LLC	0%	0
Len Blavatnik	0%	0
BML Investment Partners, L.P. 13G/A	0%	0	13G/A	2/13/2025 Event 12/31/2024
BML Investment Partners, L.P.	0%	0
Leonard Braden Michael	0%	0
MPM BioImpact LLC 13G/A	0%	0	13G/A	8/14/2026 Event 6/30/2026

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q3	1	821	$9.42 k	$0
2026 Q2	112	56.3 M	$735 M	$687 k
2026 Q1	82	32.3 M	$221 M	$592 k
2025 Q4	66	31.2 M	$158 M	$0
2025 Q3	69	44.7 M	$89.8 M	$0
2025 Q2	71	49.9 M	$61.9 M	$0
2025 Q1	77	51.9 M	$63.4 M	$0
2024 Q4	81	55.7 M	$100 M	$0
2024 Q3	73	54.7 M	$278 M	$0
2024 Q2	50	49.9 M	$355 M	$0
2024 Q1	24	16.9 M	$46.2 M	$0
2023 Q4	26	16.9 M	$45.5 M	$0
2023 Q3	24	16.7 M	$44.0 M	$0
2023 Q2	23	16.7 M	$46.8 M	$0
2023 Q1	20	16.7 M	$48.4 M	$0
2022 Q4	22	16.6 M	$61.1 M	$0
2022 Q3	23	14.8 M	$47.8 M	$0
2022 Q2	30	15.1 M	$45.7 M	$0
2022 Q1	44	17.5 M	$147 M	$0
2021 Q4	36	17.4 M	$182 M	$0
2021 Q3	33	17.3 M	$311 M	$0